Brief: Ventyx Biosciences Q2 Operating Expenses USD 35.712 Million
Aug 08 (Reuters) - Ventyx Biosciences Q2 net income USD -31.95 million vs. IBES estimate USD -38.1 million
Recent news on Ventyx Biosciences
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 (updated)
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026
Deals of the day-Mergers and acquisitions